IIG plc announces that on 2 October 2025 it completed the sale of its entire 100% holding in Touchless Innovations Limited (“Sanondaf”), to the original owner of the Sanondaf business,
IIG plc announces that on 2 October 2025 it completed the sale of its entire 100% holding in Touchless Innovations Limited (“Sanondaf”), to the original owner of the Sanondaf business,
Ondine Biomedical Strengthens Leadership Team with the Appointment of Michael Behlke as non-Board CFO & COO
Shares of Ondine Biomedical Inc. saw an increase on Friday afternoon following the announcement that the company will be raising funds to advance the commercialization of its primary antimicrobial treatment.
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
Activation of First Clinical Trial Site in the U.S
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board
Nearing All-Time Highs
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to